Skip to main content

Table 4 Clinical events during long-term follow-up

From: Real-world use of ACEI/ARB in diabetic hypertensive patients before the initial diagnosis of obstructive coronary artery disease: patient characteristics and long-term follow-up outcome

 

ACEI/ARB(-)

ACEI/ARB(+)

HR(95%CI)

P value

Overall population

 Number

1300

1201

  

 Composite MACCE

373 (28.7)

277 (23.1)

1.23 (1.06,1.44)

<0.05

 All cause death

59 (4.5)

57 (4.7)

0.92 (0.64,1.32)

NS

 CV death

49 (3.8)

37 (3.1)

1.18 (0.77,1.81)

NS

 Non-fatal MI

57 (4.4)

37 (3.1)

1.38 (0.91,2.08)

NS

 Non-fatal stroke

52 (4.0)

29 (2.4)

1.62 (1.03,2.56)

<0.05

 Revascularization

102 (7.8)

92 (7.7)

0.98 (0.74,1.29)

NS

 Cardiac rehospitalization

290 (22.3)

233 (19.4)

1.12 (0.94, 1.33)

NS

Matched population

 Number

1050

1050

  

 Composite MACCE

312 (29.7)

242 (23.1)

1.21 (1.02, 1.43)

<0.05

 All cause death

53 (5.0)

51 (4.9)

0.95 (0.65, 1.40)

NS

 CV death

44 (4.2)

33 (3.1)

1.24 (0.79, 1.94)

NS

 Non-fatal MI

48 (4.6)

31 (3.0)

1.45 (0.92, 2.28)

NS

 Non-fatal stroke

48 (4.6)

25 (2.4)

1.82 (1.13, 2.96)

<0.05

 Revascularization

76 (7.2)

81 (7.7)

0.85 (0.62, 1.16)

NS

 Cardiac rehospitalization

241 (23.0)

202 (19.2)

1.09 (0.91, 1.32)

NS

  1. ACEI/ARB angiotensin-converting enzyme inhibitor/angiotensin receptor blocker, MACCE major adverse cardiac and cerebral event, CV cardiovascular, MI myocardial infarction, HR hazard ratio, CI confidence interval, NS non-significant